BioNTech SE
BNTXDrugs in Pipeline
46
Phase 3 Programs
23
Upcoming Catalysts
6
Next Catalyst
Jul 23, 2026
10wMarket Overview
Stock performance and key metrics
7 upcoming, 2 past
BNT162b2 Vaccine
COVID-19
BNT162b2
SARS-CoV-2 Infection
BNT113
Unresectable Head and Neck Squamous Cell Carcinoma
BNT162b1
SARS-CoV-2 Infection
Biological/Vaccine: BNT162b2 10mcg
SARS-CoV-2 Infection, COVID-19
BNT162b2 OMI
SARS-CoV-2 Infection
BNT162b2 (Omi XBB.1.5)
SARS-CoV-2 Infection
BNT162b5 Bivalent (WT/OMI BA.2)
SARS-CoV-2 Infection
Seasonal Inactivated Influenza Vaccine
SARS-CoV-2 Infection
Influenza and COVID-19 Combination A
Influenza
BNT162b2 (2025/2026 formulation)
COVID-19
Pembrolizumab
Non-small Cell Lung Cancer
BNT162b2.B.1.351
SARS-CoV-2 Infection
BNT162b2 (Omi LP.8.1)
COVID-19
Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose
SARS-CoV-2 Virus
Investigational Influenza Vaccine
Influenza,Human
Pumitamig
Extensive-stage Small-cell Lung Cancer
Carboplatin
Extensive-stage Small-cell Lung Cancer
Paclitaxel
Endometrial Cancer
Gemcitabine
Breast Neoplasms
BNT324
Advanced Lung Cancer
Docetaxel
Non-small Cell Lung Cancer
Prednisone/prednisolone
Metastatic Castration-resistant Prostate Cancer
BNT166a
Monkeypox
BNT329
Advanced Solid Cancers
BNT326
Advanced Solid Tumor
BNT162b3
Covid-19
BNT111
Melanoma Stage III
BNT323
Locally Advanced Breast Cancer
Investigational COVID-19 Vaccine
Influenza
BNT314
Metastatic Colorectal Cancer
bivalent BNT162b2 (original/Omi BA.4/BA.5)
Influenza, Human
BNT162b2s01
COVID-19
BNT3214
Advanced Solid Tumor Cancer
BNT327
Non-small Cell Lung Cancer
BNT142
Solid Tumor
BNT165e
Malaria
Nab-paclitaxel
Pancreatic Ductal Adenocarcinoma (PDAC)
BNT3212
Advanced Solid Tumor
Roxadustat
Chronic Kidney Disease
BNT162a1
Infections, Respiratory
Multivalent BNT162b2 (B.1.1.7 + B.1.617.2)
SARS-CoV-2 Infection
RO7198457 intravenous (IV)
Colorectal Cancer Stage II
BNT164a1
Tuberculosis
BNT327 Dose Level 1 (DL2)
Locally Advanced Breast Cancer
Temozolomide
Recurrent Glioblastoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
BNT162b2 Vaccine | Phase 3 | COVID-19 | - | - |
BNT162b2 | Phase 3 | SARS-CoV-2 Infection | - | - |
BNT113 | Phase 3 | Unresectable Head and Neck Squamous Cell Carcinoma | - | - |
BNT162b1 | Phase 3 | SARS-CoV-2 Infection | - | - |
Biological/Vaccine: BNT162b2 10mcg | Phase 3 | SARS-CoV-2 Infection, COVID-19 | - | - |
BNT162b2 OMI | Phase 3 | SARS-CoV-2 Infection | - | - |
BNT162b2 (Omi XBB.1.5) | Phase 3 | SARS-CoV-2 Infection | - | - |
BNT162b5 Bivalent (WT/OMI BA.2) | Phase 3 | SARS-CoV-2 Infection | - | - |
Seasonal Inactivated Influenza Vaccine | Phase 3 | SARS-CoV-2 Infection | - | - |
Influenza and COVID-19 Combination A | Phase 3 | Influenza | - | - |
BNT162b2 (2025/2026 formulation) | Phase 3 | COVID-19 | - | - |
Pembrolizumab | Phase 3 | Non-small Cell Lung Cancer | - | - |
BNT162b2.B.1.351 | Phase 3 | SARS-CoV-2 Infection | - | - |
BNT162b2 (Omi LP.8.1) | Phase 3 | COVID-19 | - | - |
Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose | Phase 3 | SARS-CoV-2 Virus | - | - |
Investigational Influenza Vaccine | Phase 3 | Influenza,Human | - | - |
Pumitamig | Phase 3 | Extensive-stage Small-cell Lung Cancer | - | - |
Carboplatin | Phase 3 | Extensive-stage Small-cell Lung Cancer | - | - |
Paclitaxel | Phase 3 | Endometrial Cancer | - | - |
Gemcitabine | Phase 3 | Breast Neoplasms | - | - |
BNT324 | Phase 3 | Advanced Lung Cancer | - | - |
Docetaxel | Phase 3 | Non-small Cell Lung Cancer | - | Patent 2036 |
Prednisone/prednisolone | Phase 3 | Metastatic Castration-resistant Prostate Cancer | - | - |
BNT166a | Phase 2 | Monkeypox | - | - |
BNT329 | Phase 2 | Advanced Solid Cancers | - | - |
BNT326 | Phase 2 | Advanced Solid Tumor | - | - |
BNT162b3 | Phase 2 | Covid-19 | - | - |
BNT111 | Phase 2 | Melanoma Stage III | - | - |
BNT323 | Phase 2 | Locally Advanced Breast Cancer | - | - |
Investigational COVID-19 Vaccine | Phase 2 | Influenza | - | - |
BNT314 | Phase 2 | Metastatic Colorectal Cancer | - | - |
bivalent BNT162b2 (original/Omi BA.4/BA.5) | Phase 2 | Influenza, Human | - | - |
BNT162b2s01 | Phase 2 | COVID-19 | - | - |
BNT3214 | Phase 2 | Advanced Solid Tumor Cancer | - | - |
BNT327 | Phase 2 | Non-small Cell Lung Cancer | - | - |
BNT142 | Phase 2 | Solid Tumor | - | - |
BNT165e | Phase 2 | Malaria | - | - |
Nab-paclitaxel | Phase 2 | Pancreatic Ductal Adenocarcinoma (PDAC) | - | - |
BNT3212 | Phase 2 | Advanced Solid Tumor | - | - |
Roxadustat | Phase 2 | Chronic Kidney Disease | - | - |
BNT162a1 | Phase 2 | Infections, Respiratory | - | - |
Multivalent BNT162b2 (B.1.1.7 + B.1.617.2) | Phase 2 | SARS-CoV-2 Infection | - | - |
RO7198457 intravenous (IV) | Phase 2 | Colorectal Cancer Stage II | - | - |
BNT164a1 | Phase 2 | Tuberculosis | - | - |
BNT327 Dose Level 1 (DL2) | Phase 2 | Locally Advanced Breast Cancer | - | - |
Temozolomide | Phase 2 | Recurrent Glioblastoma | - | - |
SARS-CoV-2 Infection
8 drugs in this indication
Covid-19
4 drugs in this indication
Non-small Cell Lung Cancer
3 drugs in this indication
Advanced Solid Tumor
2 drugs in this indication
Influenza
2 drugs in this indication
Influenza, Human
2 drugs in this indication
Locally Advanced Breast Cancer
2 drugs in this indication
Extensive-stage Small-cell Lung Cancer
1 drug in this indication
Unresectable Head and Neck Squamous Cell Carcinoma
1 drug in this indication
Advanced Solid Cancers
1 drug in this indication
Metastatic Colorectal Cancer
1 drug in this indication
Advanced Lung Cancer
1 drug in this indication
Colorectal Cancer Stage II
1 drug in this indication
Monkeypox
1 drug in this indication
SARS-CoV-2 Virus
1 drug in this indication
Tuberculosis
1 drug in this indication
Solid Tumor
1 drug in this indication
Malaria
1 drug in this indication
SARS-CoV-2 Infection, COVID-19
1 drug in this indication
Infections, Respiratory
1 drug in this indication
Melanoma Stage III
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)